Dark

ONTX
Onconova Therapeutics, Inc.
stock NASDAQ

Inactive

Apr 2, 2024

0.9953USD-0.470%(-0.0047)1,281,870

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-1.00)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 4, 2022

08:00AM EST Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10, 2022, through January 13, 2022. GlobeNewswire Inc

Dec 13, 2021

08:00AM EST Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Dr. Adar Makovski Silverstein has joined Onconova as Director, Corporate Development. GlobeNewswire Inc

Dec 2, 2021

08:06AM EST Onconova Therapeutics Announces The Presentation Of Preliminary Clinical Data Providing Evidence Of Rigosertib's Activity In RDEB-associated Squamous Cell Carcinoma Benzinga

08:00AM EST Onconova Therapeutics Announces the Presentation of Preliminary GlobeNewswire Inc

Nov 22, 2021

08:00AM EST Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 29, 2021 through December 2, 2021. GlobeNewswire Inc

Nov 11, 2021

04:31PM EST Recap: Onconova Therapeutics Q3 Earnings Benzinga

04:04PM EST Onconova Therapeutics Q3 EPS $(0.22) Beats $(0.33) Estimate Benzinga

04:01PM EST Onconova Therapeutics, Inc. (NASDAQ: ONTX), (Onconova), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended September 30, 2021, and provided a business update. GlobeNewswire Inc

11:57AM EST Onconova Therapeutics Earnings Perspective: Return On Capital Employed Benzinga

03:55AM EST Earnings Scheduled For November 11, 2021 Benzinga

Nov 10, 2021

11:02AM EST Earnings Outlook For Onconova Therapeutics Benzinga

Nov 4, 2021

08:00AM EDT Onconova Therapeutics to Provide Corporate Update and Announce GlobeNewswire Inc

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Sep 30, 2021

11:21AM EDT Onconova Therapeutics's Return On Capital Employed Overview Benzinga

Sep 29, 2021

08:00AM EDT Onconova Therapeutics to Attend the Sachs 21st Annual Biotech in GlobeNewswire Inc

Sep 28, 2021

04:06PM EDT Onconova Therapeutics Announces Closing Of $21M Public Offering; Shares Move Higher Benzinga

04:05PM EDT Onconova Therapeutics, Inc. Announces Closing of $21 Million GlobeNewswire Inc

Sep 24, 2021

03:08PM EDT Mid-Day Market Update: Aehr Test Systems Surges Following Q1 Results; Onconova Therapeutics Shares Slide Benzinga

03:06PM EDT Mid-Afternoon Market Update: Dow Rises 40 Points; Meredith Shares Spike Higher Benzinga

12:13PM EDT Mid-Day Market Update: Aehr Test Systems Surges Following Q1 Results; Onconova Therapeutics Shares Slide Benzinga

10:29AM EDT Mid-Morning Market Update: Markets Mixed; Nike Sales Miss Views Benzinga

08:36AM EDT Onconova Therapeutics Prices Public Offering Of 5 Mln Shares At $4.20/Shr RTTNews

08:00AM EDT Onconova Therapeutics Prices 5M Share Offering At $4.20/Share Benzinga

08:00AM EDT Onconova Therapeutics,Inc. Announces Pricing of $21 GlobeNewswire Inc

Sep 23, 2021

04:01PM EDT Onconova Therapeutics Reports Offering Of Common Stock, No Size Disclosed Benzinga

04:01PM EDT Onconova Therapeutics,Inc. Announces Proposed Public GlobeNewswire Inc

Sep 22, 2021

03:27PM EDT Why Onconova Therapeutics Shares Are Surging Today Benzinga

03:16PM EDT Mid-Afternoon Market Update: Dow Surges Over 400 Points; Stitch Fix Shares Spike Higher Benzinga

12:38PM EDT Mid-Day Market Update: Nasdaq Jumps 100 Points; InnovAge Shares Plummet Benzinga

08:03AM EDT Onconova Therapeutics Reports Preliminary Data From Phase 1/2a Trial Of Rigosertib Plus Immune Checkpoint Inhibitor Nivolumab, Which Are Being Presented At 3rd Annual RAS Targeted Drug Development Summit Benzinga

08:02AM EDT Onconova Therapeutics Preliminary Data From Phase 1/2a Trial Of Rigosertib Plus Immune Checkpoint Inhibitor Nivolumab, Which Are Being Presented At 3rd Annual RAS Targeted Drug Development Summit Benzinga

08:00AM EDT Preliminary Phase 1/2a trial data show an early signal of activity in extensively pre-treated population with 2 partial responses out of 7 evaluable patients GlobeNewswire Inc

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Sep 20, 2021

08:00AM EDT Onconova Therapeutics Announces Upcoming Presentation at the 3rd GlobeNewswire Inc

Sep 19, 2021

09:46AM EDT The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions and Conference Presentations In The Spotlight Benzinga

Sep 9, 2021

08:00AM EDT Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021. GlobeNewswire Inc

Aug 12, 2021

05:25PM EDT Recap: Onconova Therapeutics Q2 Earnings Benzinga

05:13PM EDT Onconova Therapeutics Q2 EPS $(0.27) Beats $(0.28) Estimate, Sales $57.00K Beat $20.00K Estimate Benzinga

04:05PM EDT Onconova Therapeutics, Inc. (NASDAQ: ONTX) (Onconova), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended June 30, 2021 and provided a business update. GlobeNewswire Inc

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

04:14AM EDT Earnings Scheduled For August 12, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Jun 28, 2021

08:29AM EDT Onconova Therapeutics Provides Update On Phase 1/2a Trial Of Rigosertib-Nivolumab Combination In KRAS+ NSCLC RTTNews

08:28AM EDT Onconova Therapeutics Provides Update Oh Phase 1/2 Trial Of Rigosertib-Nivolumab Combination; Says Expansion Of Trial Underway At Highest Dose Benzinga

08:00AM EDT Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration GlobeNewswire Inc

Jun 22, 2021

08:05AM EDT Onconova Therapeutics Reports Regained Compliance With Nasdaq Continued Listing Requirement Benzinga

08:00AM EDT Onconova Therapeutics Regains Compliance with Nasdaq Continued GlobeNewswire Inc

Jun 17, 2021

08:05AM EDT Onconova Therapeutics Announces Peer-Reviewed Publication Of Preclinical Data Demonstrating Synergistic Anti-Cancer Activity Of Rigosertib Combined With Immune Checkpoint Blockade Benzinga

08:00AM EDT Rigosertib synergistically combined with immune checkpoint blockade (ICB) to improve tumor growth inhibition and survival in a murine melanoma model that did not respond to ICB alone GlobeNewswire Inc

Jun 10, 2021

08:00AM EDT Onconova Therapeutics, Inc. (NASDAQ: ONTX) (Onconova), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Companys management team will participate in A.G.P.s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021. GlobeNewswire Inc

Jun 3, 2021

08:00AM EDT Onconova Therapeutics, Inc. (NASDAQ: ONTX) (Onconova), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova has been selected to present at 2021 BIO Digital, being held virtually June 10-11 and 14-18, 2021. GlobeNewswire Inc

May 21, 2021

10:22AM EDT Mid-Morning Market Update: Markets Open Higher; Deere Beats Q2 Estimates Benzinga

08:05AM EDT Onconova Therapeutics Reports Initial Dosing Of First Patient In US Phase 1 Trial On ON123300 Benzinga

08:00AM EDT Onconova Therapeutics Announces the Initial Dosing of the First GlobeNewswire Inc

07:26AM EDT The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying Benzinga

May 20, 2021

08:34AM EDT Onconova Therapeutics Reports 1-For-15 Reverse Stock Split, Effective May 20, 2021 Benzinga

08:32AM EDT Onconova Therapeutics AnnouncesReverse Stock Split and GlobeNewswire Inc

May 18, 2021

02:38PM EDT Mid-Afternoon Market Update: Nasdaq Turns Negative; Ultralife Shares Spike Higher Benzinga

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021 Benzinga

06:32AM EDT Guggenheim Initiates Coverage On Onconova Therapeutics with Buy Rating, Announces Price Target of $4 Benzinga

May 17, 2021

04:16PM EDT Onconova Therapeutics Q1 EPS $(0.02) Beats $(0.03) Estimate Benzinga

04:05PM EDT Onconova Therapeutics Reports First Quarter 2021 Financial Results GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For May 17, 2021 Benzinga

May 14, 2021

10:29AM EDT Earnings Outlook for Onconova Therapeutics Benzinga

May 10, 2021

08:00AM EDT Onconova Therapeutics to Provide Corporate Update and Announce GlobeNewswire Inc

May 3, 2021

07:56AM EDT Onconova Therapeutics Filing Shows Shareholder Approval Of Reverse Stock Split Between 1-for-5 And 1-for-15 Benzinga

Apr 22, 2021

08:15AM EDT Onconova Announces First Patient Dosed In Investigator-Initiated Phase 2 Study Of Rigosertib In Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma Benzinga

08:00AM EDT Onconova Announces First Patient Dosed in Investigator-Initiated GlobeNewswire Inc

Apr 6, 2021

09:07AM EDT Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly Benzinga

Apr 1, 2021

09:37AM EDT Onconova Therapeutics Shareholders Reject Reverse Stock Split Benzinga

08:05AM EDT Onconova Therapeutics Partner HanX Has Enrolled Three Patients In Second Dosing Cohort Of Phase 1 Study Of ON 123300 Benzinga

08:00AM EDT Onconova Therapeutics Announces Enrollment in Second Cohort of GlobeNewswire Inc

Mar 29, 2021

08:00AM EDT Onconova to Present at the Spring 2021 Oncology Investor Conference GlobeNewswire Inc

Mar 11, 2021

04:23PM EST Onconova Therapeutics Reports FY20 EPS $(0.14) Up From $(1.49) YoY Benzinga

04:05PM EST Onconova Therapeutics Reports Full Year 2020 Financial Results, GlobeNewswire Inc

08:19AM EST The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga

03:35AM EST Earnings Scheduled For March 11, 2021 Benzinga

Mar 4, 2021

04:15PM EST Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 11, 2021 GlobeNewswire Inc

Mar 1, 2021

08:00AM EST Onconova Therapeutics, Inc. (NASDAQ: ONTX) (Onconova), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President and Chief Executive Officer, will participate in three virtual investment conferences during the month of March, as follows: GlobeNewswire Inc

Feb 24, 2021

08:29AM EST Onconova Therapeutics Regains Compliance With Nasdaq Continued Listing Requirement Benzinga

08:00AM EST Onconova Therapeutics Regains Compliance with Nasdaq Continued GlobeNewswire Inc

Feb 22, 2021

09:47AM EST 5 Value Stocks In The Healthcare Sector Benzinga

Feb 19, 2021

07:25AM EST The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko Benzinga

Feb 18, 2021

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

Feb 16, 2021

04:42PM EST Onconova Therapeutics Closing Of Offering Shows Raised Size Of Offering From 25M Shares To 28.75M Shares Benzinga

04:03PM EST Onconova Therapeutics,Inc. Announces Closing of $28.75 GlobeNewswire Inc

08:00AM EST Onconova Therapeutics to Present Corporate Update at the 2021 BIO GlobeNewswire Inc

Feb 10, 2021

10:49PM EST Onconova Therapeutics,Inc. Announces Pricing of $25 GlobeNewswire Inc

04:04PM EST Onconova Therapeutics Reports Offering Of Common Stock, No Size Disclosed Benzinga

04:01PM EST Onconova Therapeutics, Inc. Announces Proposed Public Offering of GlobeNewswire Inc

Feb 4, 2021

11:55AM EST Return On Capital Employed Overview: Onconova Therapeutics Benzinga

Jan 25, 2021

09:49AM EST 5 Value Stocks In The Healthcare Sector Benzinga

Jan 14, 2021

08:00AM EST Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event GlobeNewswire Inc

Jan 7, 2021

09:42AM EST Onconova Therapeutics, Inc. Announces $8.7M Offering At $0.445/Share Benzinga

09:42AM EST Onconova Therapeutics Reports $8.7 Mln Public Offering RTTNews

09:40AM EST Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering GlobeNewswire Inc

Dec 22, 2020

11:19AM EST Noble Capital Markets Earlier Upgraded Onconova Therapeutics to Outperform Benzinga

Dec 21, 2020

08:15AM EST Onconova Report Receipt Of FDA Permission For Phase 1 Study To Proceed Under IND For ON 123300 RTTNews

08:04AM EST Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300 Benzinga

08:00AM EST Onconova Therapeutics Announces FDA Permission for Study to GlobeNewswire Inc

Dec 1, 2020

10:27AM EST Return On Capital Employed Overview: Onconova Therapeutics Benzinga

Nov 23, 2020

08:02AM EST Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300 Benzinga

08:00AM EST -- U.S. Phase 1 trial patient enrollment to begin in the first half of 2021 -- China Phase 1 trial enrollment ongoing -- Key regulatory milestone achieved to enable further study of product candidate for patients with HR+ HER 2- metastatic breast cancer and other tumors GlobeNewswire Inc

Nov 12, 2020

04:26PM EST Onconova Therapeutics Q3 EPS $(0.03), Inline, Sales $66.00K Miss $1.39M Estimate Benzinga

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

04:18AM EST Earnings Scheduled For November 12, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 5, 2020

08:00AM EST Onconova Therapeutics to Provide Corporate Update and Third GlobeNewswire Inc

Oct 13, 2020

08:00AM EDT Onconova Therapeutics to GlobeNewswire Inc

Oct 5, 2020

09:45AM EDT 5 Value Stocks To Watch In The Healthcare Sector Benzinga

Sep 21, 2020

10:08AM EDT Looking Into Onconova Therapeutics's Return On Capital Employed Benzinga

08:14AM EDT Onconova Begins Phase 1 Clinical Trial In China For ON 123300 By HanX Biopharmaceuticals RTTNews

08:12AM EDT Onconova Therapeutics Announces Initiation Of Phase 1 Clinical Trial Of ON 123300 In China By Partner HanX Biopharmaceuticals; Co Says Remains On Track To File U.S. IND In Q4 2020 With Phase 1 Set For Q1 2021 Benzinga

08:00AM EDT Company remains on track to file a US IND in Q4 2020, with commencement of a US Phase 1 study targeted for Q1 2021 GlobeNewswire Inc

Sep 9, 2020

08:00AM EDT Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company plans to participate in several upcoming events: GlobeNewswire Inc

Aug 31, 2020

08:41AM EDT Overview Of Value Stocks In The Healthcare Sector Benzinga

08:06AM EDT Onconova Therapeutics Names James Marino As Chairman Of Board RTTNews

08:00AM EDT Onconova Therapeutics Announces Election of James J. Marino, JD, GlobeNewswire Inc

Aug 24, 2020

11:15AM EDT Return On Capital Employed Overview: Onconova Therapeutics Benzinga

10:14AM EDT HC Wainwright & Co. Downgrades Onconova Therapeutics to Neutral Benzinga

07:57AM EDT Biopharmaceutical company Onconova Therapeutics, Inc. (ONTX) said Monday that INSPIRE, the company's pivotal Phase 3 study assessing the efficacy and safety of IV rigosertib in higher-risk myelodysplastic syndromes (MDS) or HR-MDS patients, did not meet its primary endpoint of improved survival. RTTNews

07:33AM EDT Onconova Therapeutics Says Phase 3 INSPIRE Trial Did Not Meet Primary Endpoint Of Improved Survival RTTNews

07:33AM EDT Onconova Therapeutics Phase 3 INSPIRE Trial Did Not Meet its Primary Endpoint Benzinga

07:30AM EDT IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodysplastic syndromes (HR-MDS) GlobeNewswire Inc

07:30AM EDT Onconova Therapeutics Shares Halted, News Pending Benzinga

Aug 12, 2020

04:37PM EDT Onconova Therapeutics: Q2 Earnings Insights Benzinga

04:19PM EDT Onconova Therapeutics Q2 EPS $(0.04) Misses $(0.03) Estimate, Sales $56.00K Miss $170.00K Estimate Benzinga

04:05PM EDT -- INSPIRE Phase 3 trial survival events reached -- Topline data anticipated Q3-2020 GlobeNewswire Inc

04:21AM EDT Earnings Scheduled For August 12, 2020 Benzinga

Aug 7, 2020

08:00AM EDT Onconova Therapeutics to Provide Corporate Update and Second GlobeNewswire Inc

Aug 4, 2020

08:33AM EDT Onconova Therapeutics Announces Compliance With Nasdaq Bid Price Requirement Benzinga

08:00AM EDT Onconova Therapeutics Announces Compliance with Nasdaq Bid Price GlobeNewswire Inc

Jul 29, 2020

01:31PM EDT Obconova Therapeutics Announces That The Required Number Of Survival Events Has Been Reached For The Pivotal Phase 3 INSPIRE Trial Data Analysis Benzinga

01:30PM EDT Onconova Therapeutics Announces that the GlobeNewswire Inc

Jul 27, 2020

08:15AM EDT Onconova Submits Application For Rigosertib To Participate In Federally Funded Human Studies In COVID-19 Disease RTTNews

08:05AM EDT Onconova Therapeutics Submits Application For Rigosertib To Participate In Federally Funded Human Studies In Coronavirus Benzinga

08:01AM EDT Preclinical experiments with rigosertib in cellular models demonstrate marked inhibition of SARS-CoV-2 replication GlobeNewswire Inc

Jul 23, 2020

08:08AM EDT Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib's Mechanism Of Action As A Targeted Anticancer Therapy Benzinga

08:00AM EDT Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the publication (Molecular Cell 79, 180-190, 2020) of in vitro data further supporting rigosertibs role in modulating RAS cellular signaling. GlobeNewswire Inc